GeoVax Advances Vaccine Innovation and Trust on World Immunization Day

GeoVax Labs, Inc. recognized World Immunization Day by emphasizing the critical need to address declining vaccine confidence while advancing innovative vaccine technologies. The clinical-stage biotechnology company highlighted the importance of restoring public trust through transparent, science-driven vaccine development as surveys show decreasing confidence in newer vaccines and the institutions promoting them despite over 90% of Americans supporting routine childhood immunization.

David A. Dodd, Chairman & CEO of GeoVax, stated that vaccination remains one of the most powerful tools in modern medicine, preventing millions of deaths annually. He emphasized the company's commitment to advancing next-generation vaccines that address current threats while restoring public trust through rigorous science and diversified solutions. This approach comes at a crucial time when the "trust gap" underscores the need for companies to communicate openly with patients, providers, and policymakers.

GeoVax's strategy centers on diversified vaccine platforms designed to provide broader, more durable immune responses. The company's multi-antigen vaccine candidates include its COVID-19 vaccine GEO-CM04S1 and its GEO-MVA platform for Mpox and smallpox. These technologies represent a significant advancement beyond single-antigen or mRNA-only approaches, particularly important for vulnerable populations. With more than 40 million immunocompromised individuals in the United States alone, GeoVax's focus includes ensuring protection for patients underserved by current vaccine options.

The company is also advancing continuous cell line manufacturing to expand supply, reduce costs, and support U.S. preparedness. This manufacturing commitment aligns with federal initiatives to strengthen domestic biodefense while providing solutions to global health needs. By developing made-in-America vaccine capabilities, GeoVax positions itself as a leader in both national security and global health innovation.

Dodd added that Americans still believe in the power of vaccines, but the challenge lies in ensuring that belief extends to the next generation of vaccines. By prioritizing innovation alongside openness and trust, GeoVax aims to build a future where immunization continues to save lives and protect communities worldwide. The company's progress can be tracked through their corporate website at https://www.geovax.com where updates on clinical trials and development programs are regularly posted.